Advertisement

Basal and Postglucagon C-Peptide Levels in Ethiopians with Diabetes

  1. Elias S Siraj, MD1,
  2. S. Sethu K Reddy, MD1,
  3. Werner A Scherbaum, MD2,
  4. Jemal Abdulkadir, MD3,
  5. Jeffrey P Hammel, MS4 and
  6. Charles Faiman, MD1
  1. 1Department of Endocrinology Diabetes and Metabolism, Cleveland Clinic Foundation, Cleveland, Ohio
  2. 2Department of Internal Medicine III, University of Leipzig, Leipzig, Germany
  3. 3Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia
  4. 4Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Cleveland, Ohio

    Abstract

    OBJECTIVE—To study basal C-peptide (BCP) and postglucagon C-peptide (PGCP) levels in Ethiopians with diabetes.

    RESEARCH DESIGN AND METHODS—A total of 56 subjects with type 1 diabetes, 97 subjects with type 2 diabetes, and 50 control subjects were recruited from a hospital in Ethiopia. BCP was determined in all subjects and PGCP in 86 subjects.

    RESULTS—Mean (±SEM) BCP, PGCP, and the increment after glucagon in type 1 diabetic subjects (0.14 ±0.04, 0.22 ±0.11, and 0.08 ±0.05 nmol/l, respectively) were lower (P < 0.001) than those in type 2 diabetic subjects (0.66 ±0.04, 1.25 ±0.10, and 0.56 ±0.06 nmol/l, respectively) or control subjects (0.54 ±0.04, 1.52 ±0.26, and 1.11 ±0.24 nmol/l, respectively). The mean BCP level was higher in type 2 diabetic subjects than control subjects (P=0.015), whereas the mean increment was lower (P=0.005). Insulin-treated type 2 diabetic subjects, compared with non-insulin-treated type 2 diabetic subjects, had lower mean BCP (0.55 ±0.08 nmol/l [n=37] vs. 0.73 ±0.04 [n=60], P=0.001), lower PGCP (0.97 ±0.20 nmol/l [n=18] vs. 1.40 ±0.11 [n=35], P=0.010), and a lower C-peptide increment (0.34 ±0.06 [n=18] vs. 0.67 ±0.07 nmol/l [n=35], P=0.003). In both the type 1 and type 2 diabetic groups, those with BCP levels <0.2 nmol/l had lower BMI than those with higher BCP levels (P=0.023 and P < 0.001, respectively).

    CONCLUSIONS—Combined with clinical criteria, C-peptide levels are good discriminators between type 1 and type 2 diabetes in Ethiopians and may also be useful in identifying subjects with type 2 diabetes who require insulin therapy. There is a subgroup of type 2 diabetic subjects with features of type 1 diabetes.

    Footnotes

    • Address correspondence and reprint requests to Charles Faiman, MD, Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic Foundation A-53, 9500 Euclid Ave., Cleveland, OH 44195. E-mail: faimanc1{at}ccf.org.

      Received for publication 4 May 2001 and accepted in revised form 6 December 2001.

      A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    | Table of Contents
    Advertisement